Profile: Spectrum Pharmaceuticals Inc (SPPI.OQ)
22 Nov 2017
Spectrum Pharmaceuticals, Inc., incorporated on November 18, 2002, is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin's lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM). It also has three drugs in mid-to-late stage development, which include ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for immediate intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer (NMIBC), and POZIOTINIB, a pan- human epidermal growth factor receptor (HER) inhibitor used in the treatment of patients with a range of solid tumors, including breast and lung cancer.
The Company's commercialized products include FUSILEV, FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ and EVOMELA. FUSILEV is approved as a ready-to-use solution, and as freeze-dried powder. FUSILEV is used for rescue after high-dose methotrexate (MTX) therapy in osteosarcoma; in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced mCRC, and to diminish the toxicity and counteract the effects of impaired MTX elimination and of inadvertent over dosage of folic acid antagonists. FOLOTYN (pralatrexate injection) is a folate analogue metabolic inhibitor. FOLOTYN is meant for the treatment of relapsed or refractory Peripheral T Cell Lymphoma (PTCL). FOLOTYN is being investigated in a Phase I study in combination with the CHOP chemotherapy regimen. ZEVALIN is approved in the United States and more than 40 countries outside the United States, including countries in Europe, Latin America and Asia for treatment of patients with recurring, low-grade or follicular B-cell NHL after other anticancer drugs are no longer working, and newly diagnosed follicular NHL following a response to initial anticancer therapy.
MARQIBO is a sphingomyelin/cholesterol liposome-encapsulated formulation of the Food and Drug Association (FDA)-approved anticancer drug vincristine. MARQIBO's approved indication is for the treatment of adult patients with acute lymphoblastic lymphoma (ALL) in second or greater relapse or whose disease has progressed following two or more lines of anti-leukemia therapy. In addition to its approved indication, MARQIBO is being investigated in pediatric ALL in a Phase I investigator-initiated study in the United States. BELEODAQ (belinostat) is a histone deacytelase (HDAC) inhibitor for the treatment of patients with relapsed or refractory PTCL. BELEODAQ has been investigated in a Phase I study in combination with the CHOP chemotherapy regimen. EVOMELA is intended for use as a high-dose conditioning treatment prior to autologous stem cell transplant (ASCT) for patients with MM.
ROLONTIS is being investigated for the treatment of chemotherapy-induced neutropenia. A Phase II clinical study of ROLONTIS was completed. QAPZOLA is a bio-reductive alkylating indoloquinone that is enzymatically activated by enzymes that are over expressed by bladder tumors that is being tested in NMIBC. POZIOTINIB is an oral pan-HER inhibitor that irreversibly blocks signaling through the Epidermal Growth Factor Receptor (EGFR, HER) Family of tyrosine-kinase receptors, including HER1 (erbB1; EGFR), HER2 (erbB2), HER4 (erbB4), and HER receptor mutations. POZIOTINIB has shown single agent activity in the treatment of various cancer types, including breast, gastric, colorectal and lung cancers.
The Company competes with AstraZeneca plc, Bayer AG, Endo International plc, Eli Lilly and Company, Novartis International AG, Roche Holding AG, Bristol-Myers Squibb Company, Seattle Genetics, Inc., GlaxoSmithKline plc, Biogen Inc., Astellas Pharma Inc., Teva Pharmaceutical Industries Ltd., Sanofi S.A., Pfizer, Inc., Merck & Company, Inc., Celgene Corporation, Sanofi S.A., Sanofi Genzyme, Shire plc, AbbVie Inc., Poniard Pharmaceuticals, Inc. and Johnson & Johnson.
Spectrum Pharmaceuticals Inc
11500 S Eastern Ave Ste 240
HENDERSON NV 89052-5576
Company Web Links
- BRIEF-Spectrum Pharmaceuticals reports Q3 non-GAAP loss per share of $0.11
- BRIEF-Spectrum Pharmaceuticals announces initiation of a multicenter phase 2 trial of poziotinib in non-small cell lung cancer patients with Exon 20 insertion mutation in EGFR or HER2
- BRIEF-Spectrum Pharma to exchange $69.5 million in principal amount of its 2.75% convertible senior notes due 2018 for common stock and cash
- BRIEF-Spectrum Pharmaceuticals provides update on at-the-market facility
- BRIEF-Spectrum Pharma starts phase 3 qapzola trial